An Open Label Trial Evaluating Cardiac T2 in Beta-thalassemia Patients on Deferasirox (ICL670) Treatment for 18 Months

Trial Profile

An Open Label Trial Evaluating Cardiac T2 in Beta-thalassemia Patients on Deferasirox (ICL670) Treatment for 18 Months

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Deferasirox (Primary)
  • Indications Beta-thalassaemia
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top